Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Emerin is a serine-rich nuclear membrane protein consisting of 254 amino acids (∼29 kDa). It contains an N-terminal LEM domain allowing interaction with nuclear lamins and DNA-binding proteins (such as BAF), which is essential for maintaining nuclear architecture and organizing chromatin. Highly expressed in cardiac and skeletal muscle, emerin is crucial for nuclear envelope integrity, regulation of gene expression, and myogenic differentiation. Mutations in the *EMD* gene cause Emery–Dreifuss muscular dystrophy, a rare X-linked disorder characterized by skeletal muscle wasting, joint contractures, and life-threatening cardiac arrhythmias. Emerin interacts with various nuclear proteins (lamins, HDAC3, chromatin modifiers) to coordinate chromatin tethering, gene silencing, and nuclear lamina reformation, especially during cell division and differentiation. Loss of emerin disrupts nuclear mechanics and gene regulation, leading to the pathology noted in EDMD and related conditions.
Not applicable, as no drugs directly target emerin
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Emerin (EMD).